«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

21卷

期数:

2015年04期

页码:

332-334

栏目:

临床医学

出版日期:

2015-07-15

文章信息/Info

Title:

 Effect and safety of second-line pemetrexed in patients with advanced large cell lung cancer

文章编号:

1006-8147（2015）04-0332-03

作者:

 李静敏;  王华庆

（天津医科大学肿瘤医院淋巴瘤内科，国家肿瘤临床医学研究中心，天津市“肿瘤防治”重点实验室，天津 300060）

Author(s):

 LI Jing-min; WANG Hua-qing

(Department of Lymphoma, Cancer Institute and Hospital, Tianjin Medical University, National Clinical Research Center of Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China)

关键词:

培美曲塞; 多西他赛; 晚期肺大细胞癌; 疗效

Keywords:

 ; pemetrexed; docetaxel; advanced ;  large cell lung cancer;  efficacy

分类号:

R734.2

DOI:

-

文献标志码:

A

摘要:

目的: 以多西他赛为阳性对照，评价培美曲塞单药二线治疗大细胞癌的疗效及安全性。方法: 该研究选取了19例一线化疗方案失败的ⅢB或Ⅳ期肺大细胞癌患者。随机将患者分为试验组（n=11），接受培美曲塞（500 mg/m²），第1天，21 d为1周期；对照组（n=8），应用多西他赛（75 mg/m²），第1天，21 d为1周期。比较两组患者无进展生存期（PFS）、总缓解率（ORR）、临床获益率（CBR）、总生存期（OS）以及不良反应。分析两种单药化疗方案的疗效和安全性。结果: 试验组和对照组ORR分别为18.18%，12.50%，差异无统计学意义，P=0.735。两组中位PFS分别为112 d、86 d；CBR分别为57.26%和48.72%；OS分别为355 d、312 d；以上3个观察指标试验组均高于对照组，但差异无统计学意义，P值分别为0.165、0.190、0.606。试验组、对照组分别完成（3.27+1.78）、(2.76+1.54)个化疗周期，差异有统计学意义（P<0.05）。培美曲塞组粒细胞、血小板减少发生率及脱发症状明显低于多西他赛组(P<0.05)；而培美曲塞组皮疹发生率高于多西他赛组，具有统计学意义(P<0.05)。结论: 培美曲塞单药二线治疗晚期肺大细胞癌，疗效与多西他赛相似，且不良反应少，耐受性、依从性较好，安全性更高，适合晚期肺大细胞癌的临床应用。

Abstract:

Objective: To evaluate the effect and safety of pemetrexed in large cell lung cancer(LCLC). Methods: Nineteen patients with stage IIIB/IV LCLC were included, and all patients failed on first-line chemotherapy treatment. Patients were randomly divided into experimental group (n=11) and control group (n=8), receiving pemetrexed (500 mg/m²) and docetaxel (75 mg/m²)， respectively on day 1 of each 21-day cycle. The progression-free survival (PFS), overall response rate (ORR), clinical benefit rate (CBR), overall survival (OS) and the occurrence of adverse reactions were observed. Results: ORR values were 18.18% in pemetrexed versus 12.50% (P=0.735) in docetaxel group. Median PFS values were 112 days and 86 days (P=0.165), CBR were 57.26% and 48.72% (P=0.190), OS were 355 days and 312 days (P=0.606) for pemetrexed and docetaxel group, respectively. No statistical differences were found between the above indicators. Experimental group and control group completed (3.27+1.78), (2.76+1.54) cycles respectively, and the difference was statistically significant (P < 0.05). Adverse reactions were myelosuppression, nausea and vomiting, alopecia, and transient liver function abnormalities. Pemetrexed-treated patients had significantly lower hematologic toxicity (P<0.05), on the contrary, the rash incidence is lower in docetaxel group (P<0.05). Conclusion: The similar effect, superior tolerability and obedience of pemetrexed comparing with docetaxel in this study support the use of single-agent, second-line pemetrexed for advanced LCLC.

参考文献/References:

[1] Ferlay J, Shin H R, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008[J]. Int J Cancer, 2010,127(12):2893

[2] Zarogoulidis K, Zarogoulidis P, Darwiche K, et al. Treatment of non-small cell lung cancer (NSCLC)[J]. J Thorac Dis, 2013,5( Suppl 4):S389

[3] Kim Y H, Hirabayashi M, Togashi Y, et al. Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902[J]. Cancer Chemother Pharmacol, 2012,70(2):271

[4] 朱军，陈晓峰，张慧君. 大细胞肺癌术后预后的危险因素及生存分析[J]. 临床肺科杂志, 2009,14(4):489

[5] Hanagiri T, Oka S, Takenaka S, et al. Results of surgical resection for patients with large cell carcinoma of the lung[J]. Int J Surg, 2010,8(5):391

[6] Battafarano R J, Fernandez F G, Fau Ritter J, Ritter J , et al. Large cell neuroendocrine carcinoma: an aggressive form of non-small cell lung cancer[J]. - J Thorac Cardiovasc Surg, 2005,130(1):166

[7] 赵峻，薛奇，程贵余，等. 107例大细胞肺癌诊治分析[J]. 肿瘤学杂志,2009，15(3):213

[8] 徐启明，周乃康，刘颖，等. 58例肺大细胞癌的诊断和外科治疗[J]. 中国肿瘤临床,2008，35(1):15

[9] Tassinari D, Drudi F, Lazzari-Agli L, et al. Second-line treatments of advanced non-small-cell lung cancer: new evidence for clinical practice[J]. Ann Oncol, 2010,21(2):428

[10] Hanna N, Shepherd F A, Fossella F V, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy[J]. J Clin Oncol, 2004,22(9):1589

[11] 郑积华，林金容，谢波，等. 培美曲塞与多西他赛二线随机分组治疗晚期非小细胞肺癌对比分析[J]. 中华肿瘤防治杂志, 2013，12(5):368

[12] Perng R P, Shih J F, Chen Y M, et al. A phase II study of single-agent docetaxel chemotherapy for non-small cell lung cancer[J]. Jpn J Clin Oncol, 2000,30(10):429

[13] Fidias P, Novello S. Strategies for prolonged therapy in patients with advanced non-small-cell lung cancer[J]. J Clin Oncol, 2010,28(34):5116

[14] Sun C T, Xu X, Sheng W, et al. A meta-analysis of pemetrexed-based doublet compared with pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer[J]. Bratisl Lek Listy, 2014,115(4):233

相似文献/References:

[1]魏强,齐灿,罗飞,等.转移性去势抵抗性前列腺癌患者多西他赛化疗的预后分析[J].天津医科大学学报,2013,19(05):390.
[2]钱兴运,郎娟娟,陶若琳,等.左卡尼汀对多西他赛在NCI-H520细胞中抗肿瘤作用影响的研究[J].天津医科大学学报,2018,24(05):390.
　QIAN Xing-yun,LANG Juan-juan,TAO Ruo-lin,et al.Influence of l-carnitine on the antitumor effects of docetaxel in NCI-H520 cells[J].Journal of Tianjin Medical University,2018,24(04):390.

备注/Memo

备注/Memo:

作者简介 李静敏（1990-），女，硕士在读，研究方向：淋巴瘤内科学；通信作者：王华庆, E-mail: huaqingw@163.com。

常用功能

更新日期/Last Update: 2015-07-17